To include your compound in the COVID-19 Resource Center, submit it here.

Advicor: Phase III results; approved for marketing

Results of a double-blind dose-ranging U.S. Phase III trial comparing Advicor to lovastatin monotherapy in 164 patients with type IIA/IIB hyperlipidemia showed that patients given tablets

Read the full 265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE